Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Cost of RevenueEBIATGross ProfitShares OutstandingShares Outstanding
Ratios

Goldenwell Biotech (GWLL) Cost of Revenue (2021 - 2024)

Goldenwell Biotech filings provide 4 years of Cost of Revenue readings, the most recent being -$73.0 for Q4 2024.

  • On a quarterly basis, Cost of Revenue fell 139.04% to -$73.0 in Q4 2024 year-over-year; TTM through Sep 2025 was -$73.0, a 128.52% decrease, with the full-year FY2024 number at $75.0, down 93.59% from a year prior.
  • Cost of Revenue hit -$73.0 in Q4 2024 for Goldenwell Biotech, down from $69.0 in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $20663.0 in Q3 2022 to a low of -$73.0 in Q4 2024.
  • Median Cost of Revenue over the past 4 years was $360.5 (2021), compared with a mean of $2705.9.
  • Biggest five-year swings in Cost of Revenue: skyrocketed 278.19% in 2023 and later tumbled 139.04% in 2024.
  • Goldenwell Biotech's Cost of Revenue stood at $2329.0 in 2021, then soared by 787.2% to $20663.0 in 2022, then plummeted by 99.1% to $187.0 in 2023, then crashed by 139.04% to -$73.0 in 2024.
  • The last three reported values for Cost of Revenue were -$73.0 (Q4 2024), $69.0 (Q2 2024), and $187.0 (Q4 2023) per Business Quant data.